Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMARCA2 | P51531 | 11/20 | 0.37 |
| ▸ | SMARCA4 | P51532 | 11/20 | 0.37 |
| ▸ | PBRM1 | Q86U86 | 11/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.36 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | NR1I2 | O75469 | 5/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.33 |
| ▸ | IKBKB | O14920 | 2/20 | 0.33 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24461486 | 0.90 | HSD11B1 (0.38) | SMARCA2SMARCA4PBRM1HSD11B1CAMKK2 | |
| SCHEMBL24461462 | 0.88 | CAMKK2 (0.40) | SMARCA2SMARCA4PBRM1HSD11B1CAMKK2 | |
| SCHEMBL24461129 | 0.88 | SMARCA2 (0.45) | SMARCA2SMARCA4PBRM1HSD11B1CAMKK2 | |
| SCHEMBL24461458 | 0.87 | SMARCA2 (0.36) | SMARCA2SMARCA4PBRM1HSD11B1CAMKK2 | |
| SCHEMBL24461322 | 0.85 | SMARCA2 (0.37) | SMARCA2SMARCA4PBRM1HSD11B1CAMKK2 | |
| SCHEMBL24461491 | 0.84 | PBRM1 (0.36) | SMARCA2SMARCA4PBRM1HSD11B1CAMKK2 | |
| SCHEMBL24461319 | 0.84 | CCNT1 (0.38) | SMARCA2SMARCA4PBRM1HSD11B1CAMKK2 | |
| SCHEMBL24461315 | 0.83 | KDM4E (0.39) | SMARCA2SMARCA4PBRM1BRD4NR1I2 | |
| SCHEMBL24461244 | 0.82 | BRD4 (0.48) | SMARCA2SMARCA4PBRM1HSD11B1BRD4 | |
| SCHEMBL24461401 | 0.81 | PBRM1 (0.36) | SMARCA2SMARCA4PBRM1HSD11B1CAMKK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024488-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240024488-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-01-25 | — | — | US | disclosed |
| WO-2022109426-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2022-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240024488-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | SMARCA2 14/4885SMARCA4 6/4885PBRM1 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.